Latest On Akebia Therapeutics, Inc (AKBA):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-31 16:35 EST | News | Akebia jumps 16% as Piper upgrades after updates on kidney disease candidate | N/A |  |
| 2023-05-30 10:49 EST | News | Akebia says FDA denied appeal for kidney disease candidate | N/A | |
| 2023-05-29 20:33 EST | News | Akebia Therapeutics: Buy This Undervalued Stock At Just 77% Of Revenue | N/A | |
| 2023-05-25 17:33 EST | News | Akebia inks licensing deal with German pharma for kidney disease drug | N/A | |
| 2023-05-23 08:37 EST | News | Akebia Therapeutics regains Nasdaq compliance | N/A | |
| 2023-05-22 18:32 EST | News | Akebia Therapeutics wins UK approval of vadadustat for CKD anemia | N/A | |
| 2023-05-08 20:46 EST | News | Akebia GAAP EPS of -$0.14 beats by $0.01, revenue of $40.13M misses by $6.55M | N/A | |
| 2023-05-08 20:45 EST | News | Akebia Therapeutics, Inc. (AKBA) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-05-05 23:46 EST | News | Akebia Q1 2023 Earnings Preview | N/A | |
| 2023-04-14 22:16 EST | News | Akebia to inform investors about reverse stock split | N/A | |
| 2023-04-12 00:18 EST | News | Akebia gains after rescheduling special stockholder meeting | N/A | |
| 2023-04-03 17:09 EST | News | Akebia's vadadustat meets endpoints in alternative dosing regimen | N/A | |
| 2023-03-24 22:33 EST | News | Akebia down 5% following revised proxy statement for shareholder meeting | N/A | |
| 2023-03-10 04:33 EST | News | Akebia Therapeutics, Inc. (AKBA) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-09 12:50 EST | News | Akebia GAAP EPS of -$0.04 beats by $0.15, revenue of $55.18M beats by $7.78M | N/A | |
| 2023-03-09 12:49 EST | News | Akebia off 24% after 2023 revenue range comes in below consensus | N/A | |
| 2023-03-09 12:49 EST | News | Akebia stock slumps ~20% amid 'cautious' outlook for Auryxia FY23 sales | N/A | |
| 2023-02-24 14:18 EST | News | Akebia jumps 11% on EU nod to approve kidney disorder therapy | N/A | |
| 2023-02-21 21:16 EST | News | Akebia slips as FDA issues second response on appeal for kidney disease therapy | N/A | |
| 2023-02-02 15:03 EST | News | Akebia jumps 28% after FDA nod for GSK kidney disease therapy | N/A | |
| 2022-12-29 00:04 EST | News | Akebia out-licenses ferric citrate product; terminates BioVectra supply deal | N/A | |
| 2022-12-22 10:08 EST | News | Akebia Therapeutics to submit more information on kidney disease therapy to FDA | N/A | |
| 2022-11-03 22:52 EST | News | Akebia reports mixed Q3 earnings; reaffirms FY22 Auryxia net product revenue guidance | N/A | |
| 2022-11-03 22:51 EST | News | Akebia Therapeutics, Inc. (AKBA) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-03 05:19 EST | News | Akebia Q3 2022 Earnings Preview | N/A | |
| 2022-10-07 12:34 EST | News | Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky | N/A | |
| 2022-08-06 21:06 EST | News | Akebia Therapeutics Inc. (AKBA) CEO John Butler on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-08-04 23:03 EST | News | Akebia GAAP EPS of $0.15 beats by $0.48, revenue of $126.76M beats by $77.06M | N/A | |
| 2022-08-04 07:32 EST | News | Akebia Q2 2022 Earnings Preview | N/A | |
| 2022-07-01 00:36 EST | News | Akebia regains rights to kidney disease therapy after termination of deals with Otsuka | N/A | |
| 2022-05-16 08:04 EST | News | Akebia falls as agreement with Otsuka Pharma ends | N/A | |
| 2022-05-10 01:37 EST | News | Akebia GAAP EPS of -$0.35 misses by $0.06, revenue of $61.7M beats by $17.48M | N/A | |
| 2022-05-10 01:36 EST | News | Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q1 2022 Results - Earnings Call Transcript | N/A | |
| 2022-05-09 06:03 EST | News | Akebia Q1 2022 Earnings Preview | N/A | |
| 2022-04-01 02:21 EST | News | Akebia extends slide as Wall Street reacts to FDA rejection of kidney disease drug | N/A | |
| 2022-03-31 06:34 EST | News | Akebia falls as FDA rejects kidney disease therapy | N/A | |
| 2022-03-31 06:34 EST | News | Akebia Therapeutics plummets 64% on Complete Response Letter for vadadustat | N/A | |
| 2022-03-04 18:22 EST | News | Akebia slips as JPMorgan flags regulatory risk for kidney disease drug | N/A | |
| 2022-03-01 20:39 EST | News | Akebia GAAP EPS of -$0.40 misses by $0.09, revenue of $59.61M beats by $7.84M | N/A | |
| 2022-02-22 17:44 EST | News | Akebia amends license agreement with Vifor for potential launch of kidney drug | N/A | |
| 2021-11-10 02:01 EST | News | Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2021 Results - Earnings Call Transcript | N/A | |
| 2021-11-05 00:43 EST | News | Akebia EPS misses by $0.03, misses on revenue | N/A | |
| 2021-11-05 00:42 EST | News | Q3 2021 misses for Akebia Therapeutics leads to share decline | N/A | |
| 2021-10-29 13:38 EST | News | Akebia and partner Otsuka seeks EU nod for drug to treat anemia in kidney disease | N/A | |
| 2021-09-10 16:11 EST | News | Akebia Therapeutics (AKBA) Presents At Morgan Stanley 19th Annual Global Healthcare Conference - Slideshow | N/A | |
| 2021-09-06 14:21 EST | News | Another Look At Akebia Therapeutics | N/A | |
| 2021-08-05 21:31 EST | News | Akebia EPS misses by $0.20, revenue in-line | N/A | |
| 2021-08-05 21:30 EST | News | Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q2 2021 Results - Earnings Call Transcript | N/A | |
| 2021-07-25 00:07 EST | News | NRx Pharma, Cassava Sciences lead weekly healthcare gainers; Seres Therapeutics trail | N/A | |
| 2021-07-20 18:35 EST | News | FDA accepts Akebia's vadadustat NDA for review | N/A | |
About Akebia Therapeutics, Inc (AKBA):
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
General
- Name Akebia Therapeutics, Inc
- Symbol AKBA
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 379
- Fiscal Year EndDecember
- IPO Date2014-03-20
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Gic SubIndustryBiotechnology
- Web URLhttp://www.akebia.com
View More
Valuation
- Price/Sales (Trailing 12 Mt.) 1.66
- Price/Book (Most Recent Quarter) 2.19
- Enterprise Value Revenue 1.36
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$1.26
- Next Year EPS Estimate -$0.69
- Next Quarter EPS Estimate -$0.31
- Profit Margin -130%
- Operating Margin -58%
- Return on Assets -15%
- Return on Equity -119%
- Revenue 295.31 million
- Earnings Per Share -$2.40
- Revenue Per Share $2.13
- Gross Profit 12.86 million
- Quarterly Earnings Growth -18.5%
View More
Highlights
- Market Capitalization 511.16 million
- EBITDA -167800992
- PE Ratio -5.65
- Analyst Target Price $6.71
- Book Value Per Share $1.67
View More
Share Statistics
- Shares Outstanding 153.5 million
- Shares Float 152.12 million
- % Held by Insiders 109%
- % Held by Institutions 78.78%
- Shares Short 25.5 million
- Shares Short Prior Month 26.35 million
- Short Ratio 3.03
- Short % of Float 19%
- Short % of Shares Outstanding 17%
View More
Technicals
- Beta 1.89
- 52 Week High $13.71
- 52 Week Low $2.09
- 50 Day Moving Average 3.9
- 200 Day Moving Average 3.32
View More
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
View More
Akebia Therapeutics, Inc (AKBA) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Akebia Therapeutics, Inc (AKBA) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-25 | $56.7 million | -$0.60 | -$0.42 | -43.99% |
| 2020-09-30 | 2020-11-05 | $N/A | -$0.42 | -$0.24 | -75% |
| 2020-06-30 | 2020-08-10 | $N/A | -$0.44 | -$0.47 | 6.66% |
| 2020-03-31 | 2020-05-05 | $88.48 million | -$0.47 | -$0.60 | 21.85% |
| 2019-12-31 | 2020-03-10 | $69.56 million | -$0.79 | -$0.47 | -68.59% |
| 2019-09-30 | 2019-11-12 | $91.98 million | -$0.46 | -$0.41 | -12.2% |
| 2019-06-30 | 2019-08-08 | $100.8 million | -$0.49 | -$0.36 | -38.03% |
| 2019-03-31 | 2019-05-09 | $72.67 million | -$0.62 | -$0.36 | -73.62% |
| 2018-12-31 | 2019-03-18 | $59.85 million | -$0.93 | -$0.38 | -144.74% |
| 2018-09-30 | 2018-11-08 | $53.17 million | -$0.46 | -$0.56 | 17.56% |
| 2018-06-30 | 2018-08-08 | $48.79 million | -$0.60 | -$0.42 | -42.18% |
| 2018-03-31 | 2018-05-09 | $45.93 million | -$0.48 | -$0.53 | 10.21% |
| 2017-12-31 | 2018-03-12 | $87.32 million | $0.25 | -$0.44 | 156.91% |
| 2017-09-30 | 2017-11-08 | $41.28 million | -$0.49 | -$0.46 | -6.61% |
| 2017-06-30 | 2017-08-08 | $28.52 million | -$0.53 | -$0.92 | 42.23% |
| 2017-03-31 | 2017-05-09 | $20.87 million | -$1.15 | -$0.41 | -178.79% |
| 2016-12-31 | 2017-03-06 | $1.54 million | -$0.99 | $2.17 | -145.57% |
| 2016-09-30 | 2016-11-09 | $N/A | -$0.96 | -$1.14 | 15.97% |
| 2016-06-30 | 2016-08-08 | $N/A | -$0.95 | -$0.62 | -53.23% |
| 2016-03-31 | 2016-05-05 | $N/A | -$0.70 | -$0.43 | -64.71% |
| 2015-12-31 | 2016-03-14 | $N/A | -$0.68 | -$0.61 | -11.93% |
| 2015-09-30 | 2015-11-09 | $64000 | -$0.68 | -$0.52 | -30.77% |
| 2015-06-30 | 2015-08-11 | $84000 | -$0.40 | -$0.51 | 21.57% |
| 2015-03-31 | 2015-05-11 | $105000 | -$0.53 | -$0.57 | 7.02% |
| 2014-12-31 | 2015-03-04 | $349006 | -$0.52 | -$0.65 | 20% |
| 2014-09-30 | 2014-11-10 | $180000 | -$0.47 | -$0.45 | -4.44% |
| 2014-06-30 | 2014-08-11 | $171227 | -$0.39 | -$0.52 | 25% |
| 2014-03-31 | 2014-05-12 | $N/A | -$4.35 | -$0.38 | -1044.74% |
Akebia Therapeutics, Inc (AKBA) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
Akebia Therapeutics, Inc (AKBA) Chart:
Akebia Therapeutics, Inc (AKBA) News:
Below you will find a list of latest news for Akebia Therapeutics, Inc (AKBA) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Akebia Therapeutics, Inc (AKBA) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|---|---|---|---|---|---|---|---|---|
| 2024-04-19 | 0.5 | 0.9 | CALL | 0 | 32 | 0 | TRUE | 0 | 0 |
| 2024-04-19 | 1 | 0.45 | CALL | 27 | 764 | 799.4 | TRUE | 0.05 | 0.13 |
| 2024-04-19 | 1.5 | 0.03 | CALL | 115 | 3301 | 238.78 | FALSE | -0.01 | -0.25 |
| 2024-04-19 | 2 | 0.01 | CALL | 106 | 6884 | 446.61 | FALSE | -0.03 | -0.75 |
| 2024-04-19 | 2.5 | 0.04 | CALL | 0 | 15217 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 5 | 0.03 | CALL | 0 | 4940 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 7.5 | 0.03 | CALL | 0 | 553 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 0.5 | 0.02 | PUT | 0 | 1086 | 0 | FALSE | 0 | 0 |
| 2024-04-19 | 1 | 0.03 | PUT | 4 | 18931 | 615.1 | FALSE | 0.01 | 0.5 |
| 2024-04-19 | 1.5 | 0.15 | PUT | 198 | 8465 | 278.5 | TRUE | 0.03 | 0.25 |
| 2024-04-19 | 2 | 0.65 | PUT | 6 | 4549 | 646.14 | TRUE | 0.02 | 0.03 |
| 2024-04-19 | 2.5 | 1.05 | PUT | 0 | 958 | 878.39 | TRUE | 0 | 0 |
| 2024-04-19 | 5 | 3 | PUT | 0 | 2 | 0 | TRUE | 0 | 0 |
| 2024-04-19 | 7.5 | 5.3 | PUT | 0 | 1 | 0 | TRUE | 0 | 0 |
| 2024-05-17 | 0.5 | 1.03 | CALL | 0 | 1 | 444.51 | TRUE | 0 | 0 |
| 2024-05-17 | 1 | 0.5 | CALL | 0 | 48 | 145.21 | TRUE | 0 | 0 |
| 2024-05-17 | 1.5 | 0.15 | CALL | 68 | 1288 | 122.44 | FALSE | 0 | 0 |
| 2024-05-17 | 2 | 0.09 | CALL | 6 | 1438 | 160.52 | FALSE | 0.04 | 0.8 |
| 2024-05-17 | 2.5 | 0.1 | CALL | 0 | 1461 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 5 | 0.01 | CALL | 0 | 683 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 7.5 | 0.1 | CALL | 0 | 288 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 0.5 | 0.05 | PUT | 0 | 210 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 1 | 0.01 | PUT | 0 | 588 | 0 | FALSE | 0 | 0 |
| 2024-05-17 | 1.5 | 0.2 | PUT | 64 | 1278 | 87.59 | TRUE | -0.03 | -0.13 |
| 2024-05-17 | 2 | 0.65 | PUT | 0 | 356 | 125.04 | TRUE | 0 | 0 |
| 2024-05-17 | 2.5 | 1.05 | PUT | 0 | 50 | 170.19 | TRUE | 0 | 0 |
| 2024-05-17 | 5 | 0 | PUT | 0 | 0 | 386.72 | TRUE | 0 | 0 |
| 2024-05-17 | 7.5 | 0 | PUT | 0 | 0 | 411.9 | TRUE | 0 | 0 |
| 2024-07-19 | 0.5 | 1.05 | CALL | 0 | 48 | 349.2 | TRUE | 0 | 0 |
| 2024-07-19 | 1 | 0.56 | CALL | 0 | 521 | 132.62 | TRUE | 0 | 0 |
| 2024-07-19 | 1.5 | 0.24 | CALL | 120 | 493 | 99.37 | FALSE | -0.06 | -0.2 |
| 2024-07-19 | 2 | 0.12 | CALL | 11 | 1650 | 101.1 | FALSE | -0.03 | -0.2 |
| 2024-07-19 | 2.5 | 0.1 | CALL | 0 | 6066 | 120.45 | FALSE | 0 | 0 |
| 2024-07-19 | 5 | 0.04 | CALL | 0 | 3851 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 7.5 | 0.02 | CALL | 0 | 109 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 0.5 | 0.17 | PUT | 0 | 3 | 0 | FALSE | 0 | 0 |
| 2024-07-19 | 1 | 0.1 | PUT | 0 | 1907 | 107.99 | FALSE | 0 | 0 |
| 2024-07-19 | 1.5 | 0.35 | PUT | 50 | 506 | 105.98 | TRUE | 0.03 | 0.09 |
| 2024-07-19 | 2 | 0.65 | PUT | 0 | 138 | 107.57 | TRUE | 0 | 0 |
| 2024-07-19 | 2.5 | 1.05 | PUT | 0 | 21 | 102.48 | TRUE | 0 | 0 |
| 2024-07-19 | 5 | 0 | PUT | 0 | 0 | 205.24 | TRUE | 0 | 0 |
| 2024-07-19 | 7.5 | 0 | PUT | 0 | 0 | 218.32 | TRUE | 0 | 0 |
| 2024-10-18 | 0.5 | 1 | CALL | 0 | 230 | 131.78 | TRUE | 0 | 0 |
| 2024-10-18 | 1 | 0.65 | CALL | 0 | 376 | 109.65 | TRUE | 0 | 0 |
| 2024-10-18 | 1.5 | 0.42 | CALL | 57 | 604 | 116.04 | FALSE | 0.03 | 0.08 |
| 2024-10-18 | 2 | 0.3 | CALL | 0 | 1132 | 117.4 | FALSE | 0 | 0 |
| 2024-10-18 | 2.5 | 0.17 | CALL | 8 | 2863 | 104.62 | FALSE | -0.05 | -0.23 |
| 2024-10-18 | 5 | 0.05 | CALL | 57 | 2142 | 113.3 | FALSE | 0 | 0 |
| 2024-10-18 | 7.5 | 0.05 | CALL | 1 | 345 | 136.7 | FALSE | 0.05 | 0 |
| 2024-10-18 | 0.5 | 0.04 | PUT | 5 | 68 | 125.32 | FALSE | 0.04 | 0 |
| 2024-10-18 | 1 | 0.17 | PUT | 9 | 365 | 104.2 | FALSE | -0.03 | -0.15 |
| 2024-10-18 | 1.5 | 0.42 | PUT | 0 | 603 | 110.62 | TRUE | 0 | 0 |
| 2024-10-18 | 2 | 0.75 | PUT | 0 | 966 | 106.6 | TRUE | 0 | 0 |
| 2024-10-18 | 2.5 | 1.1 | PUT | 0 | 222 | 109.56 | TRUE | 0 | 0 |
| 2024-10-18 | 5 | 0 | PUT | 0 | 0 | 185.37 | TRUE | 0 | 0 |
| 2024-10-18 | 7.5 | 0 | PUT | 0 | 0 | 219.44 | TRUE | 0 | 0 |
Latest AKBA Trades:
| Date | Shares | Price |
|---|---|---|
| Jun 13, 2022 7:59 PM EST | 500 | $0.3677 |
| Jun 13, 2022 7:59 PM EST | 200 | $0.3677 |
| Jun 13, 2022 7:59 PM EST | 200 | $0.3676 |
| Jun 13, 2022 7:59 PM EST | 200 | $0.3659 |
| Jun 13, 2022 7:59 PM EST | 100 | $0.366 |
Akebia Therapeutics, Inc (AKBA) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924320018268/0000899243-20-018268-index.htm |
| 2019-09-26 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1517022/000000000019013951/0000000000-19-013951-index.htm |
| 2019-11-18 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1517022/000000000019015597/0000000000-19-015597-index.htm |
| 2020-04-24 | UPLOAD | SEC-generated letter | https://www.sec.gov/Archives/edgar/data/1517022/000000000020003521/0000000000-20-003521-index.htm |
| 2020-10-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1517022/000009375120000964/0000093751-20-000964-index.htm |
| 2019-01-10 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1517022/000021545719000127/0000215457-19-000127-index.htm |
| 2019-02-11 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1517022/000021545719007515/0000215457-19-007515-index.htm |
| 2020-02-05 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1517022/000083423720004641/0000834237-20-004641-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030789/0000899243-18-030789-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030791/0000899243-18-030791-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030793/0000899243-18-030793-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030794/0000899243-18-030794-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030796/0000899243-18-030796-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030797/0000899243-18-030797-index.htm |
| 2018-12-13 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030933/0000899243-18-030933-index.htm |
| 2018-12-13 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030934/0000899243-18-030934-index.htm |
| 2018-12-13 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030935/0000899243-18-030935-index.htm |
| 2018-12-13 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030937/0000899243-18-030937-index.htm |
| 2018-12-13 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030939/0000899243-18-030939-index.htm |
| 2018-12-13 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030940/0000899243-18-030940-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030945/0000899243-18-030945-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030946/0000899243-18-030946-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030947/0000899243-18-030947-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030948/0000899243-18-030948-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030951/0000899243-18-030951-index.htm |
| 2018-12-13 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030952/0000899243-18-030952-index.htm |
| 2019-04-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924319010587/0000899243-19-010587-index.htm |
| 2019-04-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924319010588/0000899243-19-010588-index.htm |
| 2019-04-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924319010589/0000899243-19-010589-index.htm |
| 2019-04-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924319010590/0000899243-19-010590-index.htm |
| 2019-04-12 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924319010591/0000899243-19-010591-index.htm |
| 2020-02-14 | 5 | Annual statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924320004675/0000899243-20-004675-index.htm |
| 2020-07-02 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924320018265/0000899243-20-018265-index.htm |
| 2020-07-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000089924320018268/0000899243-20-018268-index.htm |
| 2018-12-07 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1517022/000092963818000965/0000929638-18-000965-index.htm |
| 2019-02-14 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1517022/000092963819000278/0000929638-19-000278-index.htm |
| 2020-02-13 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1517022/000110465920020227/0001104659-20-020227-index.htm |
| 2018-12-21 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1517022/000114420418066059/0001144204-18-066059-index.htm |
| 2018-11-16 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312518328400/0001193125-18-328400-index.htm |
| 2018-11-16 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1517022/000119312518328401/0001193125-18-328401-index.htm |
| 2018-11-16 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1517022/000119312518328407/0001193125-18-328407-index.htm |
| 2018-11-29 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1517022/000119312518337129/0001193125-18-337129-index.htm |
| 2018-11-30 | 425 | Prospectuses and communications, business combinations | https://www.sec.gov/Archives/edgar/data/1517022/000119312518338906/0001193125-18-338906-index.htm |
| 2018-12-13 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312518348246/0001193125-18-348246-index.htm |
| 2018-12-13 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1517022/000119312518348354/0001193125-18-348354-index.htm |
| 2018-12-20 | 8-K/A | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312518353775/0001193125-18-353775-index.htm |
| 2019-01-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312519003178/0001193125-19-003178-index.htm |
| 2019-01-07 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1517022/000119312519003657/0001193125-19-003657-index.htm |
| 2019-01-11 | SC 13D/A | General statement of acquisition of beneficial ownership | https://www.sec.gov/Archives/edgar/data/1517022/000119312519007484/0001193125-19-007484-index.htm |
| 2019-01-25 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1517022/000119312519017081/0001193125-19-017081-index.htm |
| 2019-03-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312519078247/0001193125-19-078247-index.htm |
| 2019-03-19 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 | https://www.sec.gov/Archives/edgar/data/1517022/000119312519078796/0001193125-19-078796-index.htm |
| 2019-04-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312519102254/0001193125-19-102254-index.htm |
| 2019-04-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312519109907/0001193125-19-109907-index.htm |
| 2019-04-26 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1517022/000119312519122303/0001193125-19-122303-index.htm |
| 2019-04-26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1517022/000119312519122326/0001193125-19-122326-index.htm |
| 2019-05-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312519142309/0001193125-19-142309-index.htm |
| 2019-05-09 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1517022/000119312519142313/0001193125-19-142313-index.htm |
| 2019-06-04 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312519164605/0001193125-19-164605-index.htm |
| 2019-06-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312519170194/0001193125-19-170194-index.htm |
| 2019-08-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312519216112/0001193125-19-216112-index.htm |
| 2019-08-08 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1517022/000119312519216938/0001193125-19-216938-index.htm |
| 2019-09-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312519242963/0001193125-19-242963-index.htm |
| 2019-11-05 | CORRESP | Correspondence | https://www.sec.gov/Archives/edgar/data/1517022/000119312519284615/0001193125-19-284615-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312519289404/0001193125-19-289404-index.htm |
| 2019-11-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312519290130/0001193125-19-290130-index.htm |
| 2019-11-12 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1517022/000119312519290158/0001193125-19-290158-index.htm |
| 2020-01-24 | S-8 | Securities to be offered to employees in employee benefit plans | https://www.sec.gov/Archives/edgar/data/1517022/000119312520014184/0001193125-20-014184-index.htm |
| 2020-02-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520039481/0001193125-20-039481-index.htm |
| 2020-03-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520067865/0001193125-20-067865-index.htm |
| 2020-03-12 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1517022/000119312520071680/0001193125-20-071680-index.htm |
| 2020-03-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520071688/0001193125-20-071688-index.htm |
| 2020-04-07 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520100000/0001193125-20-100000-index.htm |
| 2020-04-10 | PRE 14A | Other preliminary proxy statements | https://www.sec.gov/Archives/edgar/data/1517022/000119312520103794/0001193125-20-103794-index.htm |
| 2020-04-15 | PRER14A | Preliminary Proxy Soliciting materials | https://www.sec.gov/Archives/edgar/data/1517022/000119312520107370/0001193125-20-107370-index.htm |
| 2020-04-20 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520111645/0001193125-20-111645-index.htm |
| 2020-04-23 | DEF 14A | Other definitive proxy statements | https://www.sec.gov/Archives/edgar/data/1517022/000119312520117181/0001193125-20-117181-index.htm |
| 2020-04-23 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1517022/000119312520117193/0001193125-20-117193-index.htm |
| 2020-05-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520133106/0001193125-20-133106-index.htm |
| 2020-05-11 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1517022/000119312520139011/0001193125-20-139011-index.htm |
| 2020-05-12 | 424B5 | Prospectus [Rule 424(b)(5)] | https://www.sec.gov/Archives/edgar/data/1517022/000119312520140385/0001193125-20-140385-index.htm |
| 2020-05-12 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520140443/0001193125-20-140443-index.htm |
| 2020-05-21 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material | https://www.sec.gov/Archives/edgar/data/1517022/000119312520148687/0001193125-20-148687-index.htm |
| 2020-06-09 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520164639/0001193125-20-164639-index.htm |
| 2020-06-18 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520172476/0001193125-20-172476-index.htm |
| 2020-08-10 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520214901/0001193125-20-214901-index.htm |
| 2020-09-03 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520239118/0001193125-20-239118-index.htm |
| 2020-09-11 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520244225/0001193125-20-244225-index.htm |
| 2020-09-25 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520253955/0001193125-20-253955-index.htm |
| 2020-11-05 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000119312520286276/0001193125-20-286276-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019001674/0001562180-19-001674-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019001675/0001562180-19-001675-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019001676/0001562180-19-001676-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019001677/0001562180-19-001677-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019001679/0001562180-19-001679-index.htm |
| 2019-03-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019001680/0001562180-19-001680-index.htm |
| 2019-05-09 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019002737/0001562180-19-002737-index.htm |
| 2019-06-03 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003224/0001562180-19-003224-index.htm |
| 2019-06-05 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003338/0001562180-19-003338-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003432/0001562180-19-003432-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003433/0001562180-19-003433-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003434/0001562180-19-003434-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003435/0001562180-19-003435-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003436/0001562180-19-003436-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003437/0001562180-19-003437-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003438/0001562180-19-003438-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003439/0001562180-19-003439-index.htm |
| 2019-06-10 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003440/0001562180-19-003440-index.htm |
| 2019-08-05 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019004168/0001562180-19-004168-index.htm |
| 2019-09-04 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019004618/0001562180-19-004618-index.htm |
| 2019-11-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019005622/0001562180-19-005622-index.htm |
| 2019-11-21 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019005623/0001562180-19-005623-index.htm |
| 2019-11-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019005640/0001562180-19-005640-index.htm |
| 2019-11-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019005641/0001562180-19-005641-index.htm |
| 2019-11-22 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218019005642/0001562180-19-005642-index.htm |
| 2020-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001929/0001562180-20-001929-index.htm |
| 2020-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001930/0001562180-20-001930-index.htm |
| 2020-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001931/0001562180-20-001931-index.htm |
| 2020-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001934/0001562180-20-001934-index.htm |
| 2020-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001935/0001562180-20-001935-index.htm |
| 2020-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001936/0001562180-20-001936-index.htm |
| 2020-03-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001937/0001562180-20-001937-index.htm |
| 2020-04-07 | 3 | Initial statement of beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020002936/0001562180-20-002936-index.htm |
| 2020-04-07 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020002937/0001562180-20-002937-index.htm |
| 2020-06-02 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004068/0001562180-20-004068-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004354/0001562180-20-004354-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004355/0001562180-20-004355-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004356/0001562180-20-004356-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004357/0001562180-20-004357-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004358/0001562180-20-004358-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004359/0001562180-20-004359-index.htm |
| 2020-06-09 | 4 | Statement of changes in beneficial ownership of securities | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004360/0001562180-20-004360-index.htm |
| 2019-03-26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1517022/000156459019009340/0001564590-19-009340-index.htm |
| 2019-05-09 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1517022/000156459019017969/0001564590-19-017969-index.htm |
| 2019-08-08 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1517022/000156459019030771/0001564590-19-030771-index.htm |
| 2019-11-12 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1517022/000156459019042962/0001564590-19-042962-index.htm |
| 2020-03-12 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] | https://www.sec.gov/Archives/edgar/data/1517022/000156459020010491/0001564590-20-010491-index.htm |
| 2020-04-08 | 8-K | Current report | https://www.sec.gov/Archives/edgar/data/1517022/000156459020015926/0001564590-20-015926-index.htm |
| 2020-05-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1517022/000156459020021255/0001564590-20-021255-index.htm |
| 2019-01-09 | SC 13G | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1517022/000156761919000883/0001567619-19-000883-index.htm |
| 2020-02-13 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1517022/000156761920003336/0001567619-20-003336-index.htm |
| 2020-04-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1517022/000156761920007748/0001567619-20-007748-index.htm |
| 2020-10-09 | SC 13G/A | Statement of acquisition of beneficial ownership by individuals | https://www.sec.gov/Archives/edgar/data/1517022/000156761920017709/0001567619-20-017709-index.htm |
| 2020-08-10 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1517022/000162828020012337/0001628280-20-012337-index.htm |
| 2020-11-05 | 10-Q | Quarterly report [Sections 13 or 15(d)] | https://www.sec.gov/Archives/edgar/data/1517022/000162828020015733/0001628280-20-015733-index.htm |
| 2019-03-19 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1517022/999999999719001395/9999999997-19-001395-index.htm |
| 2019-04-30 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1517022/999999999719003600/9999999997-19-003600-index.htm |
| 2019-09-17 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1517022/999999999719006833/9999999997-19-006833-index.htm |
| 2020-02-06 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1517022/999999999720000529/9999999997-20-000529-index.htm |
| 2020-02-06 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1517022/999999999720000554/9999999997-20-000554-index.htm |
| 2020-02-19 | SEC STAFF | SEC Staff Letter: REDACTED EXHIBIT | https://www.sec.gov/Archives/edgar/data/1517022/999999999720000795/9999999997-20-000795-index.htm |
| 2020-04-24 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1517022/999999999720002132/9999999997-20-002132-index.htm |
| 2020-06-12 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1517022/999999999720003615/9999999997-20-003615-index.htm |
| 2020-07-15 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1517022/999999999720004107/9999999997-20-004107-index.htm |
| 2020-09-25 | CT ORDER | Confidential treatment order | https://www.sec.gov/Archives/edgar/data/1517022/999999999720004764/9999999997-20-004764-index.htm |
Akebia Therapeutics, Inc (AKBA) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Akebia Therapeutics, Inc (AKBA). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.Insider Ownership: 109%Institutional Ownership: 7878%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2019-08-30 | Steven Keith Burke | SVP, Chief Medical Officer | Buy | 10,000.00 | 10,000.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019004618/0001562180-19-004618-index.htm | ||
| 2019-02-28 | Rita Jain | SVP, Chief Medical Officer | Buy | 80,000.00 | 100,741.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019001679/0001562180-19-001679-index.htm | ||
| 2018-12-12 | STEVEN C GILMAN | Director | Buy | 10,231.00 | 10,231.00 | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030948/0000899243-18-030948-index.htm | ||
| 2020-02-28 | John P. Butler | CEO and President | Buy | 237,400.00 | 1,026,632.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001931/0001562180-20-001931-index.htm | ||
| 2018-12-12 | MICHAEL W ROGERS | Director | Buy | 11,229.00 | 11,229.00 | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030951/0000899243-18-030951-index.htm | ||
| 2019-04-11 | Jason Amello | SVP, CFO & Treasurer | Sell | 13,148.00 | 7.70 | 101,239.60 | 118,618.00 | https://www.sec.gov/Archives/edgar/data/1517022/000089924319010587/0000899243-19-010587-index.htm |
| 2019-02-28 | Jason Amello | SVP, CFO & Treasurer | Buy | 65,000.00 | 131,766.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019001675/0001562180-19-001675-index.htm | ||
| 2019-06-06 | ADRIAN ADAMS | Director | Buy | 13,700.00 | 13,700.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003432/0001562180-19-003432-index.htm | ||
| 2019-06-06 | Cynthia Smith | Director | Buy | 13,700.00 | 13,700.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003440/0001562180-19-003440-index.htm | ||
| 2019-06-06 | Scott A Canute | Director | Buy | 13,700.00 | 13,700.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003433/0001562180-19-003433-index.htm | ||
| 2020-02-28 | Jason Amello | SVP, CFO & Treasurer | Sell | 6,976.00 | 8.70 | 60,691.20 | 144,642.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001935/0001562180-20-001935-index.htm |
| 2019-04-11 | Michel Dahan | SVP, Chief Business Officer | Sell | 11,909.00 | 7.70 | 91,699.30 | 146,932.00 | https://www.sec.gov/Archives/edgar/data/1517022/000089924319010590/0000899243-19-010590-index.htm |
| 2019-06-06 | MAXINE GOWEN | Director | Buy | 13,700.00 | 15,000.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003436/0001562180-19-003436-index.htm | ||
| 2020-02-28 | Jason Amello | SVP, CFO & Treasurer | Buy | 30,000.00 | 151,618.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001935/0001562180-20-001935-index.htm | ||
| 2019-04-11 | Nicole R. Hadas | SVP, CLO & Secretary | Sell | 11,929.00 | 7.70 | 91,853.30 | 154,806.00 | https://www.sec.gov/Archives/edgar/data/1517022/000089924319010589/0000899243-19-010589-index.htm |
| 2019-02-28 | Michel Dahan | SVP, Chief Business Officer | Buy | 65,000.00 | 158,841.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019001677/0001562180-19-001677-index.htm | ||
| 2019-02-28 | Nicole R. Hadas | SVP, CLO & Secretary | Buy | 65,000.00 | 166,735.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019001676/0001562180-19-001676-index.htm | ||
| 2019-06-06 | Mark J Enyedy | Director | Buy | 13,700.00 | 17,443.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003434/0001562180-19-003434-index.htm | ||
| 2020-02-28 | Michel Dahan | SVP, Chief Operating Officer | Sell | 6,972.00 | 8.70 | 60,656.40 | 204,960.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001937/0001562180-20-001937-index.htm |
| 2019-06-06 | Michael Thomas Heffernan | Director | Buy | 13,700.00 | 21,186.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003437/0001562180-19-003437-index.htm | ||
| 2020-02-28 | Michel Dahan | SVP, Chief Operating Officer | Buy | 65,000.00 | 211,932.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001937/0001562180-20-001937-index.htm | ||
| 2020-02-28 | Nicole R. Hadas | SVP, Chief Legal Officer | Sell | 7,050.00 | 8.70 | 61,335.00 | 212,756.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001936/0001562180-20-001936-index.htm |
| 2020-02-28 | Nicole R. Hadas | SVP, Chief Legal Officer | Buy | 62,000.00 | 219,806.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001936/0001562180-20-001936-index.htm | ||
| 2019-06-06 | STEVEN C GILMAN | Director | Buy | 13,700.00 | 23,931.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003435/0001562180-19-003435-index.htm | ||
| 2020-06-08 | MAXINE GOWEN | Director | Sell | 4,567.00 | 12.05 | 55,032.35 | 24,133.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004358/0001562180-20-004358-index.htm |
| 2019-06-06 | MICHAEL W ROGERS | Director | Buy | 13,700.00 | 24,929.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003439/0001562180-19-003439-index.htm | ||
| 2019-05-31 | Dell Faulkingham | CCO | Buy | 25,000.00 | 25,000.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003224/0001562180-19-003224-index.htm | ||
| 2019-11-20 | Cynthia Smith | Director | Buy | 15,000.00 | 3.52 | 52,800.00 | 28,700.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019005641/0001562180-19-005641-index.htm |
| 2020-06-05 | MAXINE GOWEN | Director | Buy | 13,700.00 | 28,700.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004358/0001562180-20-004358-index.htm | ||
| 2019-11-20 | STEVEN C GILMAN | Director | Buy | 5,800.00 | 3.43 | 19,894.00 | 29,731.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019005642/0001562180-19-005642-index.htm |
| 2020-06-05 | Mark J Enyedy | Director | Buy | 13,700.00 | 31,143.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004355/0001562180-20-004355-index.htm | ||
| 2020-06-05 | Michael Thomas Heffernan | Director | Buy | 13,700.00 | 34,886.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004356/0001562180-20-004356-index.htm | ||
| 2019-11-20 | Steven Keith Burke | SVP, Chief Medical Officer | Buy | 27,000.00 | 3.58 | 96,660.00 | 37,000.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019005640/0001562180-19-005640-index.htm |
| 2018-12-12 | Mark J Enyedy | Director | Buy | 3,743.00 | 3,743.00 | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030947/0000899243-18-030947-index.htm | ||
| 2020-06-08 | Cynthia Smith | Director | Sell | 4,567.00 | 12.10 | 55,260.70 | 37,833.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004360/0001562180-20-004360-index.htm |
| 2020-06-05 | MICHAEL W ROGERS | Director | Buy | 13,700.00 | 38,629.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004357/0001562180-20-004357-index.htm | ||
| 2020-06-08 | STEVEN C GILMAN | Director | Sell | 4,567.00 | 12.08 | 55,169.36 | 38,864.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004359/0001562180-20-004359-index.htm |
| 2020-06-05 | Cynthia Smith | Director | Buy | 13,700.00 | 42,400.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004360/0001562180-20-004360-index.htm | ||
| 2020-06-05 | STEVEN C GILMAN | Director | Buy | 13,700.00 | 43,431.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004359/0001562180-20-004359-index.htm | ||
| 2018-12-12 | Jodie Pope Morrison | Director | Buy | 44,919.00 | 44,919.00 | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030952/0000899243-18-030952-index.htm | ||
| 2019-04-11 | Karen L Tubridy | SVP, Chief Development Officer | Sell | 6,075.00 | 7.70 | 46,777.50 | 55,324.00 | https://www.sec.gov/Archives/edgar/data/1517022/000089924319010588/0000899243-19-010588-index.htm |
| 2019-06-06 | Jodie Pope Morrison | Director | Buy | 13,700.00 | 58,619.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003438/0001562180-19-003438-index.htm | ||
| 2019-02-28 | Karen L Tubridy | SVP, Chief Development Officer | Buy | 30,000.00 | 61,399.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019001680/0001562180-19-001680-index.htm | ||
| 2019-02-28 | John P. Butler | CEO and President | Buy | 239,500.00 | 614,382.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019001674/0001562180-19-001674-index.htm | ||
| 2019-11-20 | ADRIAN ADAMS | Director | Buy | 50,000.00 | 3.41 | 170,500.00 | 63,700.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019005622/0001562180-19-005622-index.htm |
| 2020-06-01 | Dell Faulkingham | CCO | Sell | 6,426.00 | 11.58 | 74,413.08 | 73,574.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004068/0001562180-20-004068-index.htm |
| 2018-12-12 | Michael Thomas Heffernan | Director | Buy | 7,486.00 | 7,486.00 | https://www.sec.gov/Archives/edgar/data/1517022/000089924318030945/0000899243-18-030945-index.htm | ||
| 2020-06-05 | ADRIAN ADAMS | Director | Buy | 13,700.00 | 77,400.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020004354/0001562180-20-004354-index.htm | ||
| 2020-02-28 | Dell Faulkingham | CCO | Buy | 55,000.00 | 80,000.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001929/0001562180-20-001929-index.htm | ||
| 2019-06-03 | John P. Butler | CEO and President | Buy | 287,000.00 | 0.47 | 134,890.00 | 836,232.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019003338/0001562180-19-003338-index.htm |
| 2020-02-28 | Karen L Tubridy | SVP, Chief Development Officer | Sell | 3,454.00 | 8.70 | 30,049.80 | 84,679.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001934/0001562180-20-001934-index.htm |
| 2020-02-28 | Karen L Tubridy | SVP, Chief Development Officer | Buy | 30,000.00 | 88,133.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001934/0001562180-20-001934-index.htm | ||
| 2019-11-20 | John P. Butler | CEO and President | Buy | 50,000.00 | 3.44 | 172,000.00 | 887,732.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218019005623/0001562180-19-005623-index.htm |
| 2019-04-11 | Rita Jain | SVP, Chief Medical Officer | Sell | 4,409.00 | 7.70 | 33,949.30 | 96,332.00 | https://www.sec.gov/Archives/edgar/data/1517022/000089924319010591/0000899243-19-010591-index.htm |
| 2020-02-28 | Steven Keith Burke | SVP, Chief Medical Officer | Buy | 62,000.00 | 99,000.00 | https://www.sec.gov/Archives/edgar/data/1517022/000156218020001930/0001562180-20-001930-index.htm |